Clinical Trials Logo

Filter by:
NCT ID: NCT04756622 Not yet recruiting - Mucositis Clinical Trials

N-acetyl Cysteine for the Prevention of Oral Mucositis After Autologous Hematopoietic Cell Transplantation.

Start date: April 1, 2021
Phase: Phase 3
Study type: Interventional

Oral mucositis (OM) is a major source of morbidity in patients undergoing hematopoietic cell transplantation (HCT). N-acetyl cysteine (NAC) is an antioxidant, widely used as mucolytic agent or antidote of acetaminophen overdose hepatotoxicity. we intend to explore the safety and efficacy of NAC in the prevention of OM after high-dose chemotherapy and autologous HCT in a phase III, randomized, open label and multi-center study.

NCT ID: NCT04763057 Not yet recruiting - Deep Caries Clinical Trials

Indirect Pulp Treatment in Primary Teeth

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

Conservative approaches such as indirect pulp capping techniques became popular over the last years for the management of deep carious lesions. In particular, indirect pulp-treatment (IPT) techniques have gained remarkable attention in pediatric dentistry, mainly because children require a fast and accurate treatment, besides it enables the affected primary tooth to remain in the mouth until exfoliation without causing any pain or infection.

NCT ID: NCT04764084 Not yet recruiting - Pancreatic Cancer Clinical Trials

Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors

Start date: April 1, 2021
Phase: Phase 1
Study type: Interventional

Homologous Recombination Repair (HRR) gene mutations can be detected in many solid tumors, patients with HRR gene mutations may benefit from PARP inhibitor. Antiangiogenic drugs can induce hypoxia and increase the sensitivity to PARP inhibitor. The combination of PARP inhibitor and antiangiogenic drug can play a synergistic anti-tumor role and achieve good efficacy in HRR gene-mutated tumors. The purpose of the study is to determine the dose limiting toxicity (DLT) and maximum tolerable dose (MTD) of Niraparib plus Anlotinib in HRR gene-mutated advanced solid tumors, and evaluate the safety and effectiveness of this combination therapy preliminarily.

NCT ID: NCT04768231 Not yet recruiting - Tuberculosis Clinical Trials

Rifampicin at High Dose for Difficult-to-Treat Tuberculosis

RIAlta
Start date: April 1, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety of rifampicin given at a dose three times as the standard one, in persons with tuberculosis that belong to groups that have not been widely included in previous trials.

NCT ID: NCT04769336 Not yet recruiting - Laboratory Problem Clinical Trials

Effectiveness of Point of Care Complete Blood Cell Count Analyzer in Reducing Time to Results

Start date: April 1, 2021
Phase:
Study type: Observational

The current process for getting complete blood cell counts (CBC) results in the operating room during surgery relies on sending blood samples from the operating room to the hospital's central lab. This workflow is complex and often results in handing off the blood sample to 4 or more different staff members before arriving in the lab for analysis. This often causes delayed CBC results, which may lead to inappropriate or delayed clinical decision making. By providing prompt access to CBC results with the use of a point of care CBC analyzer, the clinical workflow efficiency can be significantly improved. This should resulting in better clinical decision making, reductions in costs, increase in patient satisfaction and facilitation of hospital processes.

NCT ID: NCT04770961 Not yet recruiting - Clinical trials for Mitral Regurgitation

Erector Spinae Plane Block for Minimally Invasive Mitral Valve Surgery

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The goal of this project is to study whether local anesthetic via the erector spinae plane (ESP) block may be beneficial in minimally invasive mitral valve surgery (MIMVS).

NCT ID: NCT04774614 Not yet recruiting - Shade Match Clinical Trials

Shade Match, Marginal Adaptation and Patient Satisfaction of VITA ENAMIC multiColor Versus IPS e.Max CAD Veneers

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

It is assumed that there will be no difference in shade match, marginal adaptation and patient satisfaction between VITA ENAMIC multiColor and IPS e.max CAD anterior laminate veneers.

NCT ID: NCT04776421 Not yet recruiting - Functional Outcome Clinical Trials

Diverting Ileostomy and Anal Functional Outcomes After Anus Preservation Surgery

Start date: April 1, 2021
Phase:
Study type: Observational

Analyze the occurrence of complications, rectal function and quality of life after anus-preserving surgery for middle and low rectal cancer, so as to evaluate the role of protective ileostomy.

NCT ID: NCT04778969 Not yet recruiting - Clinical trials for Coronary Artery Disease

Kor PCI - CAD Patients Treated With PCI: Analysis of the Korean Nationwide Health Insurance Database

Start date: April 1, 2021
Phase:
Study type: Observational

Current Status and Prognosis of Coronary artery disease patients treated with coronary intervention - Analysis of the Korean Nationwide Health Insurance Database

NCT ID: NCT04780750 Not yet recruiting - Clinical trials for Squamous Cell Carcinoma of Head and Neck

Concurent Chemoradiotherapy in Head and Neck Cancers

Start date: April 1, 2021
Phase: Phase 3
Study type: Interventional

To compare the efficacy and toxicities of the combination between weekly docitaxel and cisplatin (every3 week) concurrent with radiation versus the standard concurrent chemoradiotherapy with high dose cisplatin (100mg\m2) for locally advanced HNSCC